GlassScriptPhysician profile
Tommy C Vo
NPI 1932197498
$2,943.07
in general payments reported to CMS, 2019-2025
35 companies · $351 in 2025
The $351 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $600 · 2020: $291 · 2021: $334 · 2022: $473 · 2023: $440 · 2024: $454 · 2025: $351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,245.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $346.60 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Astrazeneca Pharmaceuticals LP | $311.70 | 2019-2025 | Fasenra, Breztri, Farxiga |
| Exact Sciences Corporation | $297.99 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $250.71 | 2019-2025 | Repatha, Otezla, Otezla |
| Stryker Corporation | $139.23 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $124.72 | 2023 | Dupixent |
| Bayer Healthcare Pharmaceuticals INC. | $118.72 | 2022-2024 | |
| Dexcom, INC. | $116.81 | 2024 | Dexcom G7 Gss (161) |
| Eisai INC. | $110.77 | 2019-2021 | |
| Novo Nordisk INC | $102.63 | 2019-2023 | Ozempic, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $91.03 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $88.63 | 2020-2021 | |
| Esperion Therapeutics, INC. | $86.51 | 2020-2021 | |
| Abbvie INC. | $76.71 | 2021-2022 | |
| Shire North American Group INC | $70.98 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $67.38 | 2022 | |
| Pfizer INC. | $60.53 | 2020-2024 | |
| Supernus Pharmaceuticals, INC. | $60.13 | 2021-2025 | Qelbree |
| Merck Sharp & Dohme LLC | $50.33 | 2019 | |
| Tris Pharma INC | $42.95 | 2023-2025 | Dyanavel Xr |
| Genentech USA, INC. | $34.65 | 2019 | |
| Abbott Laboratories | $33.64 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.50 | 2022-2024 | Jardiance |
| Glaxosmithkline, LLC. | $31.97 | 2023-2024 | Shingrix, Arexvy |
| Allergan, INC. | $23.34 | 2019 | |
| Corium, LLC | $23.34 | 2022 | |
| Astellas Pharma US INC | $18.72 | 2023 | Veozah |
| Amarin Pharma, INC. | $18.57 | 2021 | |
| Owp Pharmaceuticals, INC. | $18.41 | 2021 | |
| Cook Medical LLC | $18.24 | 2025 | Zilver Ptx |
| Neos Therapeutics, LP | $16.99 | 2019 | |
| Sanofi-Aventis U.S. LLC | $15.92 | 2022 | |
| Ironshore Pharmaceuticals INC. | $14.39 | 2022 | |
| Alexion Pharmaceuticals, INC. | $13.75 | 2021 | |
| Currax Pharmaceuticals LLC | $13.58 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tommy Vo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.